A National Consensus Survey for Current Practicein Brain Tumor Management II:Diffuse Midline Glioma and Meningioma
- Author:
Sung Kwon KIM
1
;
Hong In YOON
;
Wan-Soo YOON
;
Jin Mo CHO
;
Jangsup MOON
;
Kyung Hwan KIM
;
Se Hoon KIM
;
Young Il KIM
;
Young Zoon KIM
;
Ho Sung KIM
;
Yun-Sik DHO
;
Jae-Sung PARK
;
Ji Eun PARK
;
Youngbeom SEO
;
Kyoung Su SUNG
;
Jin Ho SONG
;
Chan Woo WEE
;
Se-Hoon LEE
;
Do Hoon LIM
;
Jung Ho IM
;
Jong Hee CHANG
;
Myung-Hoon HAN
;
Je Beom HONG
;
Kihwan HWANG
;
Chul-Kee PARK
;
Youn Soo LEE
;
Ho-Shin GWAK
;
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Brain Tumor Research and Treatment 2020;8(1):11-19
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:: The Guideline Working Group of the Korean Society for Neuro-Oncology (KSNO)conducted a nationwide questionnaire survey for diverse queries faced in the treatment of brain tumors.As part II of the survey, the aim of this study is to evaluate the national patterns of clinical practicefor patients with diffuse midline glioma and meningioma.
Methods:: A web-based survey was sent to all members of the KSNO by email. The survey included4 questions of diffuse midline glioma and 6 questions of meningioma (including 2 case scenarios).All questions were developed by consensus of the Guideline Working Group.
Results:: In the survey about diffuse midline glioma, 76% respondents performed histologicconfirmation to identify H3K27M mutation on immunohistochemical staining or sequencing methods.For treatment of diffuse midline glioma, respondents preferred concurrent chemoradiotherapy withtemozolomide (TMZ) and adjuvant TMZ (63.8%) than radiotherapy alone (34.0%). In the surveyabout meningioma, respondents prefer wait-and-see policy for the asymptomatic small meningiomawithout peritumoral edema. However, a greater number of respondents had chosen surgical resectionas the first choice for all large size meningiomas without exception, and small size meningiomaswith either peritumoral edema or eloquent location. There was no single opinion with major consensuson long-term follow-up plans for asymptomatic meningioma with observation policy. As many as68.1% of respondents answered that they would not add any adjuvant therapies for World Health Organizationgrade II meningiomas if the tumor was totally resected including dura.
Conclusion:: The survey demonstrates the prevailing clinical practice patterns for patients with diffusemidline glioma and meningioma among members of the KSNO. This information provides a pointof reference for establishing a practical guideline in the management of diffuse midline glioma andmeningioma.
